Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia

Research output: Contribution to journalArticlepeer-review

Authors

  • Raja Padidela
  • Michael P Whyte
  • Francis H Glorieux
  • Craig F Munns
  • Leanne M Ward
  • And 19 others
  • Ola Nilsson
  • Anthony Portale
  • Jill Simmons
  • Noriyuki Namba
  • Hae Il Cheong
  • Pisit Pitukcheewanont
  • Etienne Sochett
  • Wolfgang Högler
  • Koji Muroya
  • Hiroyuki Tanaka
  • Gary Gottesman
  • Andrew Biggin
  • Farzana Perwad
  • Angela Williams
  • Annabel Nixon
  • Wei Sun
  • Angel Chen
  • Alison Skrinar
  • Erik Imel

Colleges, School and Institutes

External organisations

  • University of Manchester
  • Royal Manchester Children's Hospital

Abstract

Changing to burosumab, a monoclonal antibody targeting fibroblast growth factor 23, significantly improved phosphorus homeostasis, rickets, lower-extremity deformities, mobility, and growth versus continuing oral phosphate and active vitamin D (conventional therapy) in a randomized, open-label, phase 3 trial involving children aged 1–12 years with X-linked hypophosphatemia. Patients were randomized (1:1) to subcutaneous burosumab or to continue conventional therapy. We present patient-reported outcomes (PROs) from this trial for children aged ≥ 5 years at screening (n = 35), using a Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire and SF-10 Health Survey for Children. PROMIS pain interference, physical function mobility, and fatigue scores improved from baseline with burosumab at weeks 40 and 64, but changed little with continued conventional therapy. Pain interference scores differed significantly between groups at week 40 (− 5.02, 95% CI − 9.29 to − 0.75; p = 0.0212) but not at week 64. Between-group differences were not significant at either week for physical function mobility or fatigue. Reductions in PROMIS pain interference and fatigue scores from baseline were clinically meaningful with burosumab at weeks 40 and 64 but not with conventional therapy. SF-10 physical health scores (PHS-10) improved significantly with burosumab at week 40 (least-squares mean [standard error] + 5.98 [1.79]; p = 0.0008) and week 64 (+ 5.93 [1.88]; p = 0.0016) but not with conventional therapy (between-treatment differences were nonsignificant). In conclusion, changing to burosumab improved PRO measures, with statistically significant differences in PROMIS pain interference at week 40 versus continuing with conventional therapy and in PHS-10 at weeks 40 and 64 versus baseline.

Trial registration: ClinicalTrials.gov NCT02915705

Details

Original languageEnglish
JournalCalcified Tissue International
Early online date23 Jan 2021
Publication statusE-pub ahead of print - 23 Jan 2021

Keywords

  • Burosumab, X-linked hypophosphatemia, Patient-reported outcomes, Patient-reported outcomes measurement information system